Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01925703 · ClinicalTrials.gov registry record · Phase 4

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

A Phase 4 study of Heart Failure and Iron Deficiency Anemia, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 4
Development phase
13
Enrollment target
1
Study location

NCT01925703: Completed Phase 4 study of Heart Failure and Iron Deficiency Anemia, sponsored by University of North Carolina, Chapel Hill.

NCT01925703 is a Phase 4 study of Heart Failure and Iron Deficiency Anemia that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 13 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01925703, a Phase 4 study of Heart Failure and Iron Deficiency Anemia, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 4
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

Intravenous iron replacement has been shown to benefit patients with heart failure and iron deficiency, but the weekly outpatient regimens studied to date are impractical for many patients. Our purpose is to evaluate the short-term effects and safety of an accelerated intravenous iron regimen in hospitalized patients with these two conditions.

Primary Outcome

Change in serum hemoglobin concentration compared to baseline and at follow-up within 1-4 weeks after last intravenous iron infusion

Interventions

  • DRUG Sodium ferric gluconate

Study Locations (1)

North Carolina

  • University of North Carolina Hospitals & Clinics - Chapel Hill

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2011-04
Est. Completion 2013-12
Phase Phase 4

What the finished NCT01925703 record still lists

NCT01925703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Sodium ferric gluconate is the first listed.

NCT01925703 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT01925703 about?

NCT01925703 is a clinical study titled "Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure". Intravenous iron replacement has been shown to benefit patients with heart failure and iron deficiency, but the weekly outpatient regimens studied to date are impractical for many patients. Our purpose is to evaluate the short-term effects and safety of an accelerated intravenous iron regimen in hos...

What is the current status of trial NCT01925703?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2011-04. Estimated completion is 2013-12.

What conditions does trial NCT01925703 study?

This clinical trial studies the following conditions: Heart Failure, Iron Deficiency Anemia.

What interventions are being tested in trial NCT01925703?

The interventions under investigation include: Sodium ferric gluconate (DRUG).

Who is sponsoring clinical trial NCT01925703?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01925703 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01925703's enrollment target sits among peer trials

13 378th of 397 higher than 20 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01925703, the US trial registry maintained by the National Library of Medicine. NCT01925703 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.